Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Interstitial Lung Disease Due to Systemic Disease (Disorder) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

2 recruiting trials for Interstitial Lung Disease Due to Systemic Disease (Disorder). Eligibility criteria explained in plain English.

TrialFinderData lists 2 Interstitial Lung Disease Due to Systemic Disease (Disorder) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Research is led by University of Bonn (1), Azienda Unita Sanitaria Locale di Piacenza (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Single nucleotide polymorphisms (SNP) (diagnostic_test, 1 trial), followed by 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Track Interstitial Lung Disease Due to Systemic Disease (Disorder) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06696027

AYLo - AutoimmunitY and Loss of y

The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims...

Sponsor: University of BonnEnrolling: 5001 location
RECRUITINGNCT07174102

Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography

Lung involvement is one of the most frequent extra articular involvements of rheumatoid arthritis (RA). RA related lung involvement can affect parenchyma, airway, vascular tree...

Sponsor: Azienda Unita Sanitaria Locale di PiacenzaEnrolling: 5005 locations

Frequently Asked Questions

There are currently 2 clinical trials for Interstitial Lung Disease Due to Systemic Disease (Disorder), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Interstitial Lung Disease Due to Systemic Disease (Disorder), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Interstitial Lung Disease Due to Systemic Disease (Disorder), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.